Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Find generic entry opportunities
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pulmonary delivery of active fragments of parathyroid hormone|
|Abstract:||Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment provides a pulsatile concentration profile of the PTH in the host's serum. PTH fragment compositions include dry powder formulations having the PTH present in a dry bulking powder, liquid solutions or suspensions suitable for nebulization, and aerosol propellants suitable for use in a metered dose inhaler.|
|Inventor(s):||Patton; John S. (San Carlos, CA)|
|Assignee:||Inhale Therapeutic Systems (San Carlos, CA)|
|Filing Date:||Aug 03, 1998|
|Claims:||1. A method for delivery of a biologically active N-terminal fragment of parathyroid hormone (PTH) comprising administering to a mammal a pharmaceutical composition comprising said PTH fragment together with a pharmaceutically acceptable dry bulking powder, wherein said PTH fragment is present in said pharmaceutical composition as a dry powder having a mean particulate size in the range from 0.5 .mu.m to 5 .mu.m; and |
wherein said composition is administered by inhalation.
2. A method as in claim 1, wherein the bulking powder is composed of a material selected from the group consisting of sucrose, lactose, trehalose, HSA, glycine, cellobiose, dextran, maltotriose, pectin, sodium citrate, sodium ascorbate, and mannitol.
3. A pharmaceutical composition comprising a biologically active N-terminal fragment of parathyroid hormone (PTH) present as a dry powder having a mean particulate size in the range from 0.5 .mu.m to 5 .mu.m; and a pharmaceutically acceptable dry bulking powder, wherein the PTH is present at from 1% to 25% by weight, wherein the dry powder is present as an aerosol in a gas.
4. A pharmaceutical composition as in claim 3, wherein the bulking powder is composed of a material selected from the group consisting of sucrose, lactose, trehalose, HSA, glycine, cellobiose, dextran, maltotriose, pectin, sodium citrate, sodium ascorbate, and mannitol.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.